Hopkinton drug technology company appoints new CEO
Photo | Courtesy of Google Street View
The headquarters of Phosphorex in Hopkinton
Phosphorex, a Hopkinton-based drug delivery-focused contract development and manufacturing company, has named a new CEO following a growth capital investment.
The company said on Monday that Jarlath Keating, a 25-year veteran of the biopharmaceutical industry, has been appointed as its new CEO. Keating’s appointment follows the Aug. 25 announcement of Wellesley private equity firm Ampersand Capital Partners taking over a majority stake in Phosphorex.
In his career, Keating has held senior management positions within contract research and contract manufacturing organizations. Most recently, he was president and CEO at Advanced BioScience Laboratories in Maryland, which focuses on gene therapy viral vectors and oncolytic virus applications. Before that, he worked at Burlington-based MilliporeSigma in various senior commercial roles, where he led the company’s global BioReliance commercial operations function.
Company founder Bin Wu will assume the newly created role of president and chief scientific officer.
In a press release Monday, Keating said he and Wu plan to build upon the foundation started by Wu to fulfill the company’s mission as an end-to-end contract development and manufacturing company provider for nanoparticle technologies.
Most Recent
Most Recent
0 Comments